Participated · Series A · Jul 2026

Keiron develops the HF2 LiFT Printer, a digital, non-contact platform that replaces traditional stencil printing, jet printing and SPI inspection in electronics assembly. The company reports first-pass yield improvements from an industry-typical ~60% to above 95%, a twofold reduction in production lead time, doubled production uptime, and programming that is ten times faster. Those performance gains target high-mix, low-to-medium-volume electronics production, with benefits cited for throughput, working capital and EBITDA. Keiron is a TNO spin-off and has attracted a mix of public and private investors in its recent Series A. The company plans to use the Series A proceeds to scale production and expand its market presence.

Participated · Seed · May 2026

Casimir is commercializing the MicroSparc chip, which the company says harvests energy directly from quantum vacuum fields to provide continuous power without batteries or charging cycles. The technology and fabrication work referenced DARPA-supported nanofabrication and was recently described in a peer-reviewed paper in Physical Review Research. The project is led by Harold “Sonny” White, a physicist formerly with NASA. Casimir announced an oversubscribed $12 million seed round to fund efforts to bring the chip to market. The company has positioned this financing as seed equity and disclosed a wide group of participating investors but did not report revenue, users, or a prior valuation in the article.

Led · Equity · Apr 2026

Brilliance is a photonics startup founded in 2023 by Tim Tiek (CEO) and Douwe Geuzebroek (CTO) and is based in Enschede. It develops miniature RGB laser chips built on a patented silicon nitride photonic integrated circuit (PIC) platform with integrated laser technology for use in AR projectors and related display architectures. The company claims its chips reduce power consumption by a factor of ten, increase brightness for outdoor use, and enable smaller, more energy-efficient light engines that can fit into eyewear and automotive HUDs. Brilliance says its manufacturing approach leverages established high-volume chip processes to replace complex optical assemblies. The firm plans to scale up, design custom solutions for customers, and prepare for a first production launch by the end of this year. Financially, it has raised €2 million in seed funding in 2023 and an additional €6 million in the current round led by Cottonwood Technology Fund.

Led · Seed · Feb 2026

QT Sense is a Netherlands-based life-science technology company building a precision quantum sensing platform that enables more accurate biological insights for drug discovery and spatial biology applications. The platform is positioned as an enabling layer that can expand what is measurable and actionable in complex biological systems, potentially unlocking a multi-billion-euro market opportunity. With its newly funded “AAA strategy,” the company plans a dual focus: accelerating user adoption in pharmaceutical settings while simultaneously deepening the platform’s technical capabilities and scaling manufacturing for production-quality delivery. This marks a transition from pilot projects to repeatable customer deployments. QT Sense frames the round not merely as capital but as a milestone toward a “quantum future” for life sciences, emphasizing alignment with investors on long-term vision and near-term commercialization priorities. No operating metrics such as revenue or user counts were disclosed in the article.

Participated · Seed · Dec 2025

Daisy Genomics is an Albuquerque-based startup building technology for precision medicine. The company’s platform focuses on leveraging genomic information to tailor medical treatments to individual patients. Though still early stage, Daisy Genomics has attracted investor attention for its potential to advance personalized healthcare. The firm recently secured seed financing to accelerate product development and expand its scientific and engineering team. No operating metrics such as revenue, user count, or customer numbers have been disclosed. The new capital will support continued R&D and go-to-market preparations as the company refines its precision medicine offerings.